Overview

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.

Phase:

PHASE2

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Treatments:

Bevacizumab
Fluorouracil
Leucovorin
Nivolumab
Oxaliplatin